Veterinary Report by embark

Test Date: January 9th, 2020

Customer-supplied information

Owner Name: Tammie J rendon
Dog Name: Sky
Sex: Female (intact)
Date of birth: 09/27/19
Breed type: n/a
Breed: Bernedoodle
Breed registration: n/a 933000320206018
Microchip: n/a

Genetic summary

Genetic breed identification:

Breed mix:
Poodle (Small): 71.9%
Bernese Mountain Dog: 28.1%
Predicted adult weight: 34 lbs
Calculated from 17 size genes.

Genetic age: 17 human years
Human equivalent age based on size, date of birth provided, and other factors

Karyogram (Chromosome painting)

Chromosome 1
Chromosome 2
Chromosome 3
Chromosome 4
Chromosome 5
Chromosome 6
Chromosome 7
Chromosome 8
Chromosome 9
Chromosome 10
Chromosome 11
Chromosome 12
Chromosome 13
Chromosome 14
Chromosome 15
Chromosome 16
Chromosome 17
Chromosome 18
Chromosome 19
Chromosome 20
Chromosome 21
Chromosome 22
Chromosome 23
Chromosome 24
Chromosome 25
Chromosome 26
Chromosome 27
Chromosome 28
Chromosome 29
Chromosome 30
Chromosome 31
Chromosome 32
Chromosome 33
Chromosome 34
Chromosome 35
Chromosome 36
Chromosome 37
Chromosome 38

Clinical Tools

These clinical genetic tools can inform clinical decisions and diagnoses. These tools do not predict increased risk for disease.

Alanine Aminotransferase Activity (GPT)
Sky's baseline ALT level is Low Normal
Why is this important to your vet?

Sky has one copy of a variant associated with reduced ALT activity as measured on veterinary blood chemistry panels. Please inform your veterinarian that Sky has this genotype, as ALT is often used as an indicator of liver health and Sky is likely to have a lower than average resting ALT activity. As such, an increase in Sky’s ALT activity could be evidence of liver damage, even if it is within normal limits by standard ALT reference ranges.

What is Alanine Aminotransferase Activity?

Alanine aminotransferase (ALT) is a clinical tool that can be used by veterinarians to better monitor liver health. This result is not associated with liver disease. ALT is one of several values veterinarians measure on routine blood work to evaluate the liver. It is a naturally occurring enzyme located in liver cells that helps break down protein. When the liver is damaged or inflamed, ALT is released into the bloodstream.

How vets diagnose this condition

Genetic testing is the only way to provide your veterinarian with this clinical tool.

How this condition is treated

Veterinarians may recommend blood work to establish a baseline ALT value for healthy dogs with one or two copies of this variant.

Health Report

How to interpret Sky’s genetic health results:

If Sky inherited any of the variants that we tested, they will be listed at the top of the Health Report section, along with a description of how to interpret this result. We also include all of the variants that we tested Sky for that we did not detect the risk variant for.

A genetic test is not a diagnosis

This genetic test does not diagnose a disease. Please talk to your vet about your dog’s genetic results, or if you think that your pet may have a health condition or disease.

Sky inherited one variant that you should learn more about.

Progressive Retinal Atrophy, prcd
Breed-Relevant Genetic Conditions
7 variants not detected

Additional Genetic Conditions
172 variants not detected

Health Report

Progressive Retinal Atrophy, prcd (PRCD Exon 1)
Rocky Mtn Sky inherited one copy of the variant we tested
What does this result mean?

This result should not impact Sky’s health but it could have consequences for siblings or other related dogs if they inherited two copies of the variant. We recommend discussing this result with their owners or breeders if you are in contact.

Impact on Breeding

Your dog carries this variant and will pass it on to ~50% of her offspring.

What is Progressive Retinal Atrophy, prcd?

PRA-prcd is a retinal disease that causes progressive, non-painful vision loss. The retina contains cells, called photoreceptors, that collect information about light and send signals to the brain. There are two types of photoreceptors: rods, for night vision and movement, and cones, for day vision and color. This type of PRA leads to early loss of rod cells, leading to night blindness before day blindness.

When signs & symptoms develop in affected dogs

The age affected dogs will first show signs of visual impairment varies by breed. However, most begin showing clinical signs in early adulthood.

How vets diagnose this condition

Veterinarians use a focused light to examine the pupils. In affected dogs, the pupils will appear more dilated and slower to contract. Your vet may also use a lens to visualize the retina at the back of the eye to look for changes in the optic nerve or blood vessels. You may be referred to a veterinary ophthalmologist for a definitive diagnosis.

How this condition is treated

Currently, there is no definitive treatment for PRA. Supplements, including antioxidants, have been proposed for management of the disease, but have not been scientifically proven effective.

Actions to take if your dog is affected
  • Careful monitoring by your veterinarian will be required for the rest of your affected dog's life as secondary complications, including cataracts, can develop.
  • With blind dogs, keeping furniture in the same location, making sure they are on a leash in unfamiliar territory, and training them to understand verbal commands are some of the ways to help them at home.

Breed-Relevant Conditions Tested

Sky did not have the variants that we tested for, that are relevant to her breeds:

Von Willebrand Disease Type I (VWF)
Congenital Macrothrombocytopenia (TUBB1 Exon 1, Cavalier King Charles Spaniel Variant)
GM2 Gangliosidosis (HEXB, Poodle Variant)
Degenerative Myelopathy, DM (SOD1A)
Neonatal Encephalopathy with Seizures, NEWS (ATF2)
Osteochondrodysplasia, Skeletal Dwarfism (SLC13A1)
Chondrodystrophy and Intervertebral Disc Disease, CDDY/IVDD, Type I IVDD (FGF4 retrogene - CFA12)

Additional Conditions Tested

Sky did not have the variants that we tested for, in the following conditions that the potential effect on dogs with Sky’s breeds may not yet be known.

MDR1 Drug Sensitivity (MDR1)
P2Y12 Receptor Platelet Disorder (P2Y12)
Factor IX Deficiency, Hemophilia B (F9 Exon 7, Terrier Variant)
Factor IX Deficiency, Hemophilia B (F9 Exon 7, Rhodesian Ridgeback Variant)
Factor VII Deficiency (F7 Exon 5)
Factor VIII Deficiency, Hemophilia A (F8 Exon 10, Boxer Variant)
Factor VIII Deficiency, Hemophilia A (F8 Exon 11, Shepherd Variant 1)
Factor VIII Deficiency, Hemophilia A (F8 Exon 1, Shepherd Variant 2)
Thrombopathia (RASGRP1 Exon 5, Basset Hound Variant)
Thrombopathia (RASGRP1 Exon 8)
Thrombopathia (RASGRP1 Exon 5, American Eskimo Dog Variant)
Von Willebrand Disease Type III, Type III vWD (VWF Exon 4)
Von Willebrand Disease Type III, Type III vWD (VWF Exon 7)
Von Willebrand Disease Type II, Type II vWD (VWF)
Canine Leukocyte Adhesion Deficiency Type III, CLADIII (FERMT3)
Canine Elliptocytosis (SPTB Exon 30)
Glanzmann's Thrombasthenia Type I (ITGA2B Exon 12)
May-Hegglin Anomaly (MYH9)
Prekallikrein Deficiency (KLKB1 Exon 8)
Pyruvate Kinase Deficiency (PKLR Exon 5)
Pyruvate Kinase Deficiency (PKLR Exon 7 Labrador Variant)
Pyruvate Kinase Deficiency (PKLR Exon 7 Pug Variant)
Pyruvate Kinase Deficiency (PKLR Exon 7 Beagle Variant)
Pyruvate Kinase Deficiency (PKLR Exon 10)

Additional Conditions Tested

Trapped Neutrophil Syndrome (VPS13B)
Ligneous Membranitis, LM (PLG)
Platelet factor X receptor deficiency, Scott Syndrome (TMEM16F)
Methemoglobinemia CYB5R3
Congenital Hypothyroidism (TPO, Tenterfield Terrier Variant)
Complement 3 Deficiency, C3 Deficiency (C3)
Severe Combined Immunodeficiency (PRKDC)
Severe Combined Immunodeficiency (RAG1)
X-linked Severe Combined Immunodeficiency (IL2RG Variant 1)
X-linked Severe Combined Immunodeficiency (IL2RG Variant 2)
Progressive Retinal Atrophy, rcd1 (PDE6B Exon 21 Irish Setter Variant)
Progressive Retinal Atrophy, rcd3 (PDE6A)
Progressive Retinal Atrophy, CNGA (CNGA1 Exon 9)
Progressive Retinal Atrophy (CNGB1)
Progressive Retinal Atrophy (SAG)
Golden Retriever Progressive Retinal Atrophy 1, GR-PRA1 (SLC4A3)
Golden Retriever Progressive Retinal Atrophy 2, GR-PRA2 (TTC8)
Progressive Retinal Atrophy, crd1 (PDE6B)
Progressive Retinal Atrophy - crd4/cord1 (RPGRIP1)
Collie Eye Anomaly, Choroidal Hypoplasia, CEA (NHEJ1)
Achromatopsia (CNGA3 Exon 7 German Shepherd Variant)
Achromatopsia (CNGA3 Exon 7 Labrador Retriever Variant)
Autosomal Dominant Progressive Retinal Atrophy (RHO)
Canine Multifocal Retinopathy (BEST1 Exon 2)

Additional Conditions Tested

Canine Multifocal Retinopathy (BEST1 Exon 5)
Canine Multifocal Retinopathy (BEST1 Exon 10 Deletion)
Canine Multifocal Retinopathy (BEST1 Exon 10 SNP)
Glaucoma (ADAMTS10 Exon 9)
Glaucoma (ADAMTS10 Exon 17)
Glaucoma (ADAMTS17 Exon 11)
Glaucoma (ADAMTS17 Exon 2)
Hereditary Cataracts, Early-Onset Cataracts, Juvenile Cataracts (HSF4 Exon 9 Shepherd Variant)
Primary Lens Luxation (ADAMTS17)
Congenital Stationary Night Blindness (RPE65)
Macular Corneal Dystrophy, MCD (CHST6)
2,8-Dihydroxyadenine Urolithiasis, 2,8-DHA Urolithiasis (APRT)
Cystinuria Type I-A (SLC3A1)
Cystinuria Type II-A (SLC3A1)
Cystinuria Type II-B (SLC7A9)
Hyperuricosuria and Hyperuricemia or Urolithiasis, HUU (SLC2A9)
Polycystic Kidney Disease, PKD (PKD1)
Primary Hyperoxaluria (AGXT)
Protein Losing Nephropathy, PLN (NPHS1)
X-Linked Hereditary Nephropathy, XLHN (COL4A5 Exon 35, Samoyed Variant 2)
Autosomal Recessive Hereditary Nephropathy, Familial Nephropathy, ARHN (COL4A4 Exon 3)
Primary Ciliary Dyskinesia, PCD (CCDC39 Exon 3)
Congenital Keratoconjunctivitis Sicca and Ichthyosiform Dermatosis, Dry Eye Curly Coat Syndrome, CKCSID (FAM83H Exon 5)
X-linked Ectodermal Dysplasia, Anhidrotic Ectodermal Dysplasia (EDA Intron 8)

Additional Conditions Tested

Renal Cystadenocarcinoma and Nodular Dermatofibrosis, RCND (FLCN Exon 7)
Canine Fucosidosis (FUCA1)
Glycogen Storage Disease Type II, Pompe's Disease, GSD II (GAA)
Glycogen Storage Disease Type IA, Von Gierke Disease, GSD IA (G6PC)
Glycogen Storage Disease Type IIIA, GSD IIIA (AGL)
Mucopolysaccharidosis Type I, MPS I (IDUA)
Mucopolysaccharidosis Type IIIA, Sanfilippo Syndrome Type A, MPS IIIA (SGSH Exon 6 Variant 1)
Mucopolysaccharidosis Type IIIA, Sanfilippo Syndrome Type A, MPS IIIA (SGSH Exon 6 Variant 2)
Mucopolysaccharidosis Type VII, Sly Syndrome, MPS VII (GUSB Exon 5)
Mucopolysaccharidosis Type VII, Sly Syndrome, MPS VII (GUSB Exon 3)
Glycogen storage disease Type VII, Phosphofructokinase Deficiency, PFK Deficiency (PFKM Whippet and English Springer Spaniel Variant)
Glycogen storage disease Type VII, Phosphofructokinase Deficiency, PFK Deficiency (PFKM Wachtelhund Variant)
Lagotto Storage Disease (ATG4D)
Neuronal Ceroid Lipofuscinosis 1, NCL 1 (PPT1 Exon 8)
Neuronal Ceroid Lipofuscinosis 2, NCL 2 (TPP1 Exon 4)
Neuronal Ceroid Lipofuscinosis 1, Cerebellar Ataxia, NCL4A (ARSG Exon 2)
Neuronal Ceroid Lipofuscinosis 1, NCL 5 (CLN5 Border Collie Variant)
Neuronal Ceroid Lipofuscinosis 6, NCL 6 (CLN6 Exon 7)
Neuronal Ceroid Lipofuscinosis 8, NCL 8 (CLN8 English Setter Variant)
Neuronal Ceroid Lipofuscinosis (MFSD8)
Neuronal Ceroid Lipofuscinosis (CLN8 Australian Shepherd Variant)
Neuronal Ceroid Lipofuscinosis 10, NCL 10 (CTSD Exon 5)
Neuronal Ceroid Lipofuscinosis (CLN5 Golden Retriever Variant)
Adult-Onset Neuronal Ceroid Lipofuscinosis (ATP13A2, Tibetan Terrier Variant)

Additional Conditions Tested

Late-Onset Neuronal Ceroid Lipofuscinosis (ATP13A2, Australian Cattle Dog Variant)
GM1 Gangliosidosis (GLB1 Exon 15 Shiba Inu Variant)
GM1 Gangliosidosis (GLB1 Exon 15 Alaskan Husky Variant)
GM1 Gangliosidosis (GLB1 Exon 2)
GM2 Gangliosidosis (HEXA)
Globoid Cell Leukodystrophy, Krabbe disease (GALC Exon 5)
Autosomal Recessive Amelogenesis Imperfecta, Familial Enamel Hypoplasia (Italian Greyhound Variant)
Autosomal Recessive Amelogenesis Imperfecta, Familial Enamel Hypoplasia (Parson Russell Terrier Variant)
Persistent Mullerian Duct Syndrome, PMDS (AMHR2)
Deafness and Vestibular Syndrome of Dobermans, DVDob, DINGS (MYO7A)
Shar-Pei Autoinflammatory Disease, SPAID, Shar-Pei Fever (MTBP)
Alaskan Husky Encephalopathy, Subacute Necrotizing Encephalomyelopathy (SLC19A3)
Alexander Disease (GFAP)
Cerebellar Abiotrophy, Neonatal Cerebellar Cortical Degeneration, NCCD (SPTBN2)
Cerebellar Ataxia, Progressive Early-Onset Cerebellar Ataxia (SEL1L)
Cerebellar Hypoplasia (VLDLR)
Spinocerebellar Ataxia, Late-Onset Ataxia, LoSCA (CAPN1)
Spinocerebellar Ataxia with Myokymia and/or Seizures (KCNJ10)
Benign Familial Juvenile Epilepsy, Remitting Focal Epilepsy (LGI2)
Fetal-Onset Neonatal Neuroaxonal Dystrophy (MFN2)
Hypomyelination and Tremors (FNIP2)
Shaking Puppy Syndrome, X-linked Generalized Tremor Syndrome (PLP)
Neuroaxonal Dystrophy, NAD (Spanish Water Dog Variant)
Neuroaxonal Dystrophy, NAD (Rottweiler Variant)

Additional Conditions Tested

L-2-Hydroxyglutaricaciduria, L2HGA (L2HGDH)
Polyneuropathy, NDRG1 Greyhound Variant (NDRG1 Exon 15)
Polyneuropathy, NDRG1 Malamute Variant (NDRG1 Exon 4)
Narcolepsy (HCRTR2 Intron 6)
Progressive Neuronal Abiotrophy, Canine Multiple System Degeneration, CMSD (SERAC1 Exon 15)
Progressive Neuronal Abiotrophy, Canine Multiple System Degeneration, CMSD (SERAC1 Exon 4)
Juvenile Laryngeal Paralysis and Polyneuropathy, Polyneuropathy with Ocular Abnormalities and Neuronal Vacuolation, POANV (RAB3GAP1, Rottweiler Variant)
Hereditary Sensory Autonomic Neuropathy, Acral Mutilation Syndrome, AMS (GDNF-AS)
Juvenile-Onset Polyneuropathy, Leonberger Polyneuropathy 1, LPN1 (LPN1, ARHGEF10)
Spongy Degeneration with Cerebellar Ataxia 1, SDCA1, SeSAME/EAST Syndrome (KCNJ10)
Spongy Degeneration with Cerebellar Ataxia 2, SDCA2 (ATP1B2)
Dilated Cardiomyopathy, DCM1 (PDK4)
Dilated Cardiomyopathy, DCM2 (TTN)
Long QT Syndrome (KCNQ1)
Muscular Dystrophy (DMD, Cavalier King Charles Spaniel Variant 1)
Muscular Dystrophy (DMD Pembroke Welsh Corgi Variant )
Muscular Dystrophy (DMD Golden Retriever Variant)
Exercise-Induced Collapse (DNM1)
Inherited Myopathy of Great Danes (BIN1)
Myostatin Deficiency, Bully Whippet Syndrome (MSTN)
Myotonia Congenita (CLCN1 Exon 7)
Myotonia Congenita (CLCN1 Exon 23)
Myotubular Myopathy 1, X-linked Myotubular Myopathy, XL-MTM (MTM1, Labrador Variant)
Hypocatalasia, Acatalasemia (CAT)

Additional Conditions Tested

Pyruvate Dehydrogenase Deficiency (PDP1)
Malignant Hyperthermia (RYR1)
Imerslund-Grasbeck Syndrome, Selective Cobalamin Malabsorption (CUBN Exon 53)
Imerslund-Grasbeck Syndrome, Selective Cobalamin Malabsorption (CUBN Exon 8)
Lundehund Syndrome (LEPREL1)
Congenital Myasthenic Syndrome (CHAT)
Congenital Myasthenic Syndrome (COLQ)
Episodic Falling Syndrome (BCAN)
Dystrophic Epidermolysis Bullosa (COL7A1)
Ectodermal Dysplasia, Skin Fragility Syndrome (PKP1)
Ichthyosis, Epidermolytic Hyperkeratosis (KRT10)
Ichthyosis (PNPLA1)
Ichthyosis (SLC27A4)
Ichthyosis (NIPAL4)
Focal Non-Epidermolytic Palmoplantar Keratoderma, Pachyonychia Congenita (KRT16)
Hereditary Footpad Hyperkeratosis (FAM83G)
Hereditary Nasal Parakeratosis (SUV39H2)
Musladin-Lueke Syndrome (ADAMTSL2)
Bald Thigh Syndrome (IGFBP5)
Cleft Lip and/or Cleft Palate (ADAMTS20)
Hereditary Vitamin D-Resistant Rickets (VDR)
Oculoskeletal Dysplasia 1, Dwarfism-Retinal Dysplasia, OSD1 (COL9A3, Labrador Retriever)
Osteogenesis Imperfecta, Brittle Bone Disease (COL1A2)
Osteogenesis Imperfecta, Brittle Bone Disease (SERPINH1)

Additional Conditions Tested

Osteogenesis Imperfecta, Brittle Bone Disease (COL1A1)
Skeletal Dysplasia 2, SD2 (COL11A2)
Craniomandibular Osteopathy, CMO (SLC37A2)
Chondrodystrophy, Norwegian Elkhound and Karelian Bear Dog Variant (ITGA10)

Genetic Diversity and Inbreeding

Coefficient of Inbreeding (COI)

Genetic Result:

Our genetic COI measures the proportion of your dog’s genome (her genes) where the genes on the mother’s side are identical by descent to those on the father’s side. The higher your dog’s coefficient of inbreeding (the percentage), the more inbred your dog is.

Your Dog’s COI

Coefficient of inbreeding chart

This graph represents where your dog’s inbreeding levels fall on a scale compared to both dogs with a similar breed makeup to her (the yellow dotted line) and all purebred dogs (the grey line).

Genetic Diversity and Inbreeding

More on the Science

Embark scientists, along with our research partners at Cornell University, have shown the impact of inbreeding on longevity and fertility and developed a state-of-the-art, peer-reviewed method for accurately measuring COI and predicting average COI in litters.


About Embark

Embark Veterinary is a canine genetics company offering research-grade genetic tests to pet owners and breeders. Every Embark test examines over 200,000 genetic markers, and provides results for over 170 genetic health conditions, breed identification, clinical tools, and more.

Embark is a research partner of the Cornell University College of Veterinary Medicine and collaborates with scientists and registries to accelerate genetic research in canine health. We make it easy for customers and vets to understand, share and make use of their dog’s unique genetic profile to improve canine health and happiness.

Learn more at

Veterinarians and hospitals can send inquiries to